Darvadstrocel for complex perianal Crohn's fistulae offers strong value for patients refractory to conventional therapy and biologics, particularly given it is EU-approved and reimbursed. Success rate (~50–55% healing) and durability (~40–50% at 1 year) are comparable to or superior to traditional surgical approaches (seton drainage, fistulotomy) which are mutilating. Cost (€7,500–9,500) is reasonable for potential durable healing without surgery. Systemic MSC induction therapy for active Crohn's or ulcerative colitis is less compelling: remission rates (40–55%) are similar to established biologics (TNF inhibitors, integrin antagonists), which have faster onset (2–4 weeks versus 8–12 weeks). Long-term remission without further therapy is uncertain, unlike some biologic responders. Cost (€6,000–8,000 per infusion) is comparable to biologic induction but slower, making it secondary-line for most. Best-fit candidates for systemic MSC therapy are those biologic-naïve, early disease, or unable to access/afford standard biologics; darvadstrocel fistula therapy is appropriate for all refractory perianal disease regardless of prior biologic exposure.
Crohn's disease and ulcerative colitis (inflammatory bowel disease, IBD) involve chronic intestinal inflammation driven by aberrant immune responses to commensals and barrier dysfunction. Current therapies (aminosalicylates, corticosteroids, biologics) suppress inflammation but do not repair underlying mucosal defects or fully restore immune tolerance. Stem cell strategies exploit the immunoregulatory capacity of placental mesenchymal stem cells (MSCs), which secrete anti-inflammatory cytokines (IL-10, TGF-β) and promote regulatory T cell differentiation. MSCs also enhance barrier integrity by supporting tight-junction proteins and promoting mucosal healing. A particularly important development: darvadstrocel, an allogeneic MSC product, recently obtained European Union conditional approval for treatment of complex perianal Crohn's fistulae—marking the first regulatory recognition of cell therapy for IBD. Beyond this niche indication, systemic MSC therapy for induction remission and maintenance is investigational across 89 registered trials globally; thirteen actively recruit.
Am I a candidate? → · Crohn's & IBD: full overview → · Crohn's & IBD cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם